2021
Liauw, J., Groom, K., Ganzevoort, W., Gluud, C., McKinlay, C. J. D., Sharp, A., . . . von Dadelszen, P. (2021). Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis. Systematic Reviews, 10(1). doi:10.1186/s13643-021-01849-5DOI: 10.1186/s13643-021-01849-5
Children with neonatal Hypoxic Ischaemic Encephalopathy (HIE) treated with therapeutic hypothermia are not as school ready as their peers. (Journal article)
Edmonds, C. J., Cianfaglione, R., Cornforth, C., & Vollmer, B. (2021). Children with neonatal Hypoxic Ischaemic Encephalopathy (HIE) treated with therapeutic hypothermia are not as school ready as their peers.. Acta paediatrica (Oslo, Norway : 1992), 110(10), 2756-2765. doi:10.1111/apa.16002DOI: 10.1111/apa.16002
Cervical cerclage, pessary, or vaginal progesterone in high-risk pregnant women with short cervix: a randomized feasibility study (Journal article)
Care, A., Jackson, R., O'Brien, E., Leigh, S., Cornforth, C., Haycox, A., . . . Alfirevic, Z. (2021). Cervical cerclage, pessary, or vaginal progesterone in high-risk pregnant women with short cervix: a randomized feasibility study. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 34(1), 49-57. doi:10.1080/14767058.2019.1588245DOI: 10.1080/14767058.2019.1588245
2020
Gent, J., Bullough, S., Harrold, J., Jackson, R., Woolfall, K., Andronis, L., . . . Sharp, A. (2020). The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32+0weeks' gestation. PILOT AND FEASIBILITY STUDIES, 6(1). doi:10.1186/s40814-020-00722-xDOI: 10.1186/s40814-020-00722-x
Khalil, A., Sharp, A. N., Cornforth, C., Jackson, R., Mousa, H., Stock, S., . . . Alfirevic, Z. (2020). Effect of sildenafil on maternal hemodynamics in pregnancies complicated by severe early‐onset fetal growth restriction: planned subgroup analysis from a multicenter randomized placebo‐controlled double‐blind trial. Ultrasound in Obstetrics and Gynecology, 55(2), 198-209. doi:10.1002/uog.20851DOI: 10.1002/uog.20851
2019
Sharp, A., Jackson, R., Cornforth, C., Harrold, J., Turner, M. A., Kenny, L., . . . Alfirevic, Z. (2019). A Prediction Model for Short-Term Neonatal Outcomes in Severe Early-Onset Fetal Growth Restriction. European Journal of Obstetrics and Gynecology and Reproductive Biology, 241, 109-118. doi:10.1016/j.ejogrb.2019.08.007DOI: 10.1016/j.ejogrb.2019.08.007
Sharp, A., Cornforth, C., & Alfirevic, Z. (2019). Learning from the STRIDER trial. Obstetrics, Gynaecology & Reproductive Medicine, 29(8), 240-241. doi:10.1016/j.ogrm.2019.04.011DOI: 10.1016/j.ogrm.2019.04.011
Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction (Journal article)
Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L., . . . Alfirevic, Z. (2019). Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. LANCET CHILD & ADOLESCENT HEALTH, 3(3), E2-E3. doi:10.1016/S2352-4642(19)30020-3DOI: 10.1016/S2352-4642(19)30020-3
2018
Sharp, A., Cornforth, C., Turner, M. A., Harrold, J., Kenny, L. C., Jackson, R., . . . Alfirevic, Z. (2018). Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child and Adolescent Health, 2(2), 93-102. doi:10.1016/S2352-4642(17)30173-6DOI: 10.1016/S2352-4642(17)30173-6
2017
Dopamine transporter (<i>DAT1</i>/<i>SLC6A3</i>) polymorphism and the association between being born small for gestational age and symptoms of ADHD (Journal article)
Waldie, K. E., Cornforth, C. M., Webb, R. E., Thompson, J. M. D., Murphy, R., Moreau, D., . . . Mitchell, E. A. (2017). Dopamine transporter (<i>DAT1</i>/<i>SLC6A3</i>) polymorphism and the association between being born small for gestational age and symptoms of ADHD. BEHAVIOURAL BRAIN RESEARCH, 333, 90-97. doi:10.1016/j.bbr.2017.06.040DOI: 10.1016/j.bbr.2017.06.040
2012
Children born small for gestational age are not at special risk for preschool emotion and behaviour problems. (Journal article)
Cornforth, C. M., Thompson, J. M. D., Robinson, E., Waldie, K. E., Pryor, J. E., Clark, P., . . . Mitchell, E. A. (2012). Children born small for gestational age are not at special risk for preschool emotion and behaviour problems.. Early human development, 88(7), 479-485. doi:10.1016/j.earlhumdev.2011.12.001DOI: 10.1016/j.earlhumdev.2011.12.001
Initial evidence that polymorphisms in neurotransmitter-regulating genes contribute to being born small for gestational age. (Journal article)
Morgan, A. R., Thompson, J. M. D., Waldie, K. E., Cornforth, C. M., Turic, D., Sonuga-Barke, E. J. S., . . . Mitchell, E. A. (2012). Initial evidence that polymorphisms in neurotransmitter-regulating genes contribute to being born small for gestational age.. Journal of pediatric genetics, 1(2), 103-113. doi:10.3233/pge-2012-018DOI: 10.3233/pge-2012-018
The catechol-O-methyltransferase (COMT) Val158Met polymorphism moderates the effect of antenatal stress on childhood behavioural problems: longitudinal evidence across multiple ages. (Journal article)
Thompson, J. M. D., Sonuga-Barke, E. J., Morgan, A. R., Cornforth, C. M., Turic, D., Ferguson, L. R., . . . Waldie, K. E. (2012). The catechol-O-methyltransferase (COMT) Val158Met polymorphism moderates the effect of antenatal stress on childhood behavioural problems: longitudinal evidence across multiple ages.. Developmental medicine and child neurology, 54(2), 148-154. doi:10.1111/j.1469-8749.2011.04129.xDOI: 10.1111/j.1469-8749.2011.04129.x
2010
Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. (Journal article)
Cornforth, C., Sonuga-Barke, E., & Coghill, D. (2010). Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients.. Current pharmaceutical design, 16(22), 2424-2433. doi:10.2174/138161210791959827DOI: 10.2174/138161210791959827
